Alterations in SERT and 5HT2A are directly involved in the pathophysiology of depression and represent some of the targets of antidepressant medication, which is not surprising when considering the essential roles that the serotonergic system plays in the regulation of behavioral patterns directly affected in depression, such as mood, emotion, or sleep (for a recent review of the serotonergic hypothesis of depression, see Fakboury, 2016). This evidence concerns the gene HTR2A and depressive symptom measurement.